Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist extensively studied in metabolic and appetite-regulation research.
Also referenced as: GLP-S
Overview
Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral).
At a glance
What Semaglutide does
Semaglutide is a long-acting GLP-1 receptor agonist: a modified analog of the native incretin hormone GLP-1, stabilized against DPP-4 degradation by an aminoisobutyric acid substitution and carrying a C18 fatty-diacid chain that binds albumin to give a ~7-day half-life. Its core action is to engage GLP-1 receptors across several tissues at once. On the pancreatic beta cell it amplifies glucose-dependent insulin secretion, and on the alpha cell it suppresses glucagon — both effects gated by ambient glucose, which is why in trials it lowers blood sugar with a low intrinsic hypoglycemia risk. In the SUSTAIN program (type 2 diabetes) it produced HbA1c reductions on the order of 1.5-1.8 percentage points.
Beyond glycemia, semaglutide markedly slows gastric emptying and acts on GLP-1 receptors in hypothalamic and hindbrain (area postrema, nucleus tractus solitarius) appetite circuits, reducing hunger and food intake. This CNS satiety effect is the main driver of the weight loss seen in the STEP obesity trials, where the 2.4 mg weekly dose produced roughly 15% mean body-weight reduction over 68 weeks — far beyond earlier diabetes doses. Semaglutide is one of the few peptides here with hard cardiovascular-outcome data: SUSTAIN-6 showed reduced major adverse cardiovascular events in high-risk diabetics, and SELECT (2023) demonstrated a ~20% MACE reduction in non-diabetic patients with obesity and established cardiovascular disease. It is human-clinical, regulator-approved, and among the most extensively studied compounds in this catalog.
Effects reported in research
- Amplified glucose-dependent insulin secretion from pancreatic beta cells, lowering HbA1c ~1.5-1.8% in the SUSTAIN type-2-diabetes trials (human clinical).
- Suppressed glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, reducing hepatic glucose output (human clinical).
- Slowed gastric emptying, blunting post-meal glucose spikes and prolonging satiety (human clinical).
- Reduced appetite and food intake via GLP-1 receptors in hypothalamic and hindbrain satiety centers (human clinical).
- ~15% mean body-weight reduction at 2.4 mg weekly over 68 weeks in the STEP obesity program (human clinical).
- ~20% reduction in major adverse cardiovascular events in non-diabetic obesity patients with cardiovascular disease in the SELECT trial (human clinical).
- Reduced kidney-disease progression in the FLOW trial in type 2 diabetics with chronic kidney disease (human clinical).
- Low intrinsic risk of hypoglycemia when used alone, because both its insulin and glucagon effects are glucose-dependent (human clinical).
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Semaglutide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Long-acting GLP-1 analog based on the native GLP-1 backbone with amino-acid substitutions that block DPP-4 cleavage
- Carries a C18 fatty-diacid side chain via a linker that drives strong albumin binding, extending its half-life to roughly one week
- Administered once weekly by subcutaneous injection in most trials; an oral tablet formulation co-formulated with the absorption enhancer SNAC also exists
- Marketed under distinct brand names for glycemic (Ozempic/Rybelsus) versus weight-management (Wegovy) indications
- Extensively studied in large cardiovascular and outcomes trial programs
- Acts on both peripheral glucose handling and central appetite pathways
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Semaglutide is a research compound.
In the human clinical literature semaglutide is administered once weekly with a stepwise dose-escalation to improve tolerability. These are reference figures describing what appears in published research/protocols, not dosing guidance for humans.
- Reported weekly escalation: 0.25 mg -> 0.5 mg -> 1.0 mg -> 1.7 mg -> 2.4 mg once weekly (each step ~4 weeks)
- Common maintenance references in the literature: 1.0-2.4 mg once weekly
- Rodent pharmacology studies: on the order of ~10-60 nmol/kg dosing (study-dependent)
Half-life ~7 days drives the once-weekly schedule and the multi-week escalation/washout. Reference figures for research context only.
How it compares
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Commonly studied alongside
Compounds frequently researched together with Semaglutide in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Semaglutide sits in the GLP-1 Family area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Semaglutide
For researchers studying Semaglutide, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
How is semaglutide dose-escalated in the research literature?
Published protocols use a stepwise weekly escalation, commonly 0.25 mg, then 0.5, 1.0, 1.7, and up to 2.4 mg once weekly, with each step typically held about 4 weeks. Escalation is used in the literature to reduce gastrointestinal tolerability issues rather than starting at the top dose. These are reference figures for research context only, not dosing guidance for humans.
How does semaglutide differ from tirzepatide?
Semaglutide is a single-receptor GLP-1 agonist, whereas tirzepatide is a dual GLP-1/GIP receptor agonist. In head-to-head research the dual-agonist mechanism is associated with larger effects on body weight and glycemic endpoints in the models studied. Semaglutide remains the more extensively characterized reference compound.
Is semaglutide an approved drug?
Yes — semaglutide is an approved pharmaceutical in injectable and oral formulations for glycemic and weight-management indications in humans. In a research-peptide catalog context it is handled strictly as a reference research chemical, and material sold for research is not a substitute for the approved product and is not for human use.
How is lyophilized semaglutide typically reconstituted in research settings?
Lyophilized semaglutide is commonly reconstituted with bacteriostatic water, with the diluent volume chosen to give a convenient concentration for the study's measurement units. Once reconstituted it is generally kept refrigerated and protected from light, and freeze-thaw cycles are avoided. A COA/HPLC purity report (commonly greater than or equal to 98%) is the standard quality reference to expect.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.